Home > Insider Trading > Filing (0001140361-11-027462)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1006045	Iridex Corp	IRIX	Electromedical & Electrotherapeutic Apparatus (3845)	770210467

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1311443	Blueline Partners, L.l.c.	319 Diablo Road Ste 200 Danville CA 94526	No	No	Yes	No
1338149	Blueline Capital Partners, L.p.	319 Diablo Road Ste 200 Danville CA 94526	No	No	Yes	No
1411986	Blueline Capital Partners Iii, Lp	319 Diablo Road Ste 200 Danville CA 94526	No	No	Yes	No
1411987	Blueline Partners Ii, Llc	319 Diablo Road Ste 200 Danville CA 94526	No	No	Yes	No
1460518	Blueline Catalyst Fund Ix, L.p.	319 Diablo Road Suite 200 Danville CA 94526	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2011-05-11	5,442	$3.68	2,535,736	No	4	P	Direct
Common Stock	Disposition	2011-05-12	1,200	$3.69	2,536,936	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Direct

Footnotes

(1) As described in Amendment No. 4 to Schedule 13D ("Amendment No. 4") filed on October 25, 2007 with respect to the securities owned by BlueLine Capital Partners, L.P., BlueLine Capital Partners II, L.P., BlueLine Capital Partners III, L.P., BlueLine Catalyst Fund VIII, L.P., BlueLine Catalyst Fund IX, L.P., BlueLine Partners, L.L.C., and BlueLine Partners II, L.L.C., as of the date of Amendment No. 4, the Reporting Entities may have been deemed to be a "group" under Section 13(d) of the Securities Exchange Act and accordingly each Reporting Entity may have been deemed to have beneficial ownership of 10% or more of the securities.The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, any Reporting Person is the beneficial owner of any Common Stock covered by this statement.